Search
Epidermolysis Bullosa Clinical Trials
A listing of 3 Epidermolysis Bullosa clinical trials actively recruiting volunteers for paid trials and research studies in various therapeutic areas.
1 - 3 of 3
Match to Clinical Trials
Access to cutting-edge treatments
Latest clinical trials
Find trials in your area
Search by Name
Filter by Condition
Epidermolysis Bullosa
Filter by Age
Filter by Type
Gender
Type of Study
Clinical Trial Phase
There are currently 3 active clinical trials seeking participants for Epidermolysis Bullosa research studies. The states with the highest number of trials for Epidermolysis Bullosa participants are California, Illinois, Minnesota and Texas.
Featured Trial
Healthy Participants Needed (Colonoscopy + Cancer Screening)
Recruiting
Earn $325 - $475 in electronic payment card compensation for your time and effort by participating in a clinical study to develop a blood test that may one day help screen for colon cancer. Take a quick quiz to see if you qualify.
Conditions:
Healthy
Healthy Volunteers
Healthy Subjects
Healthy Volunteer
Healthy Participants
Featured Trial
Buy Retatrutide Online Through Celia
Recruiting
Retatrutide (formerly M25) is an investigational peptide being studied for its potential in supporting weight management and metabolic health. It acts on GLP-1, GIP, and glucagon receptors to influence appetite, energy regulation, and fat metabolism.
Conditions:
Healthy
Featured Offer
Lose 20% of Body Weight With GLP-1's
Policy Lab has partnered with OnlineSemaglutide.org to offer trusted access to tirzepatide and other GLP-1 medications, including generic alternatives to Ozempic® and Wegovy®.
Semaglutide and Tirzepatide are advanced GLP-1 medications designed to support weight management and metabolic health. They work by targeting GLP-1 receptors in the body, helping regulate appetite, improve blood sugar control, and support sustainable weight loss (up to 22% of body weight).
Get $50 off your first order using promo code: policy-lab-50
Semaglutide and Tirzepatide are advanced GLP-1 medications designed to support weight management and metabolic health. They work by targeting GLP-1 receptors in the body, helping regulate appetite, improve blood sugar control, and support sustainable weight loss (up to 22% of body weight).
Get $50 off your first order using promo code: policy-lab-50
Conditions:
Overweight
Overweight and Obesity
Obesity
Weight Loss
Morbid Obesity
Featured Trial
Birth Control Clinical Research Study
Recruiting
Living with obesity and looking for a birth control option that is right for you? Clinical trials are now enrolling women with a body mass index (BMI) of 30 or more in the area to help study a potential new progestin-only contraceptive patch. Participating in research studies can help advance birth control options. Don’t let financial stress hold you back. All study-related assessments, care, and study patch are available at no cost. You may also be reimbursed for study-related travel.
Conditions:
Obesity
Overweight
Overweight and Obesity
Targeting Collagen VII Antibodies With IV IgG in Dystrophic Epidermolysis Bullosa
Recruiting
The study objective is to see if IV IgG treatment in Recessive Dystrophic Epidermolysis Bullosa (RDEB) skin in conjunction with VYJUVEK treatment improves wound healing and affects the levels of C7 and HSV-1 antibody levels in serum.
Fewer wounds, more rapidly healing wounds, and decreased C7 and HSV-1 antibodies could improve quality of life.
Gender:
ALL
Ages:
6 years and above
Trial Updated:
07/31/2025
Locations: Stanford University, Redwood City, California
Conditions: Epidermolysis Bullosa, Epidermolysis Bullosa Acquisita, Dystrophic Epidermolysis Bullosa, Recessive Dystrophic Epidermolysis Bullosa
Computational Drug Repurposing for All EBS Cases
Recruiting
The study will compare gene expression differences between blistered and non-blistered skin from individuals with all subtypes of EB, as well as normal skin from non-EB subjects. State of the art computational analysis will be performed to help identify new drugs that might help all EB wound healing and reduce pain. Researchers will focus on drugs that have already been approved for treatment of other dermatologic or non-dermatologic diseases, and therefore be repurposed for treatment of EB. Dru... Read More
Gender:
ALL
Ages:
0 years and above
Trial Updated:
02/11/2024
Locations: Pediatric Dermatology Clinic at Stanford Children's Hospital, Palo Alto, California
Conditions: Epidermolysis Bullosa Simplex, Healthy, Genetic Skin Disease, Epidermolysis Bullosa, Epidermolysis Bullosa, Junctional, Epidermolysis Bullosa Dystrophica
Allogeneic ABCB5-positive Dermal Mesenchymal Stromal Cells for Treatment of Epidermolysis Bullosa (Phase III)
Recruiting
The aim of this clinical trial is to investigate the safety and efficacy of allo-APZ2-OTS administered intravenously to subjects with recessive dystrophic epidermolysis bullosa (RDEB) compared to placebo.
Gender:
ALL
Ages:
6 months and above
Trial Updated:
10/27/2023
Locations: Masonic Cancer Center and Medical Center Minneapolis, Minneapolis, Minnesota
Conditions: Epidermolysis Bullosa
1 - 3 of 3